Jonathan Kropski
-
December 20, 2021
“Atlas” of lung development may aid efforts to heal premature lungs
Researchers at Vanderbilt University Medical Center have constructed a single-cell “atlas” of lung development that tracks multiple cell types over time. -
November 18, 2020
Why does COVID-19 seem to spare children? Vanderbilt University Medical Center study offers an answer
Researchers at Vanderbilt University Medical Center (VUMC) and their colleagues have determined a key factor as to why COVID-19 appears to infect and sicken adults and older people preferentially while seeming to spare younger children. -
July 8, 2020
New clues to lung-scarring disease may aid treatment
Scientists at Vanderbilt University Medical Center and the Translational Genomics Research Institute (TGen) in Phoenix, Arizona, have discovered previously unreported genetic and cellular changes that occur in the lungs of people with pulmonary fibrosis (PF). -
May 27, 2020
Research probes why COVID-19 seems to spare young children
Lung disease experts at Vanderbilt University Medical Center (VUMC) and their colleagues have determined a key factor as to why COVID-19 appears to infect and sicken adults and older people preferentially while seeming to spare younger children. -
November 14, 2019
VUMC researchers set for Cutting-Edge Discovery Lecture
Antiviral immunity, obesity and pulmonary fibrosis will be discussed by three Vanderbilt University researchers during a Cutting-Edge Discovery Lecture on Nov. 21. The lecture will begin at 4 p.m. in 208 Light Hall. -
April 18, 2019
Medical Societies honor multiple Vanderbilt faculty
Several Vanderbilt faculty members were recently honored during the joint annual meeting of the Association of American Physicians (AAP) and American Society for Clinical Investigation (ASCI). -
February 1, 2018
Study tracks therapy to slow idiopathic pulmonary fibrosis
Investigators in the Division of Allergy, Pulmonary and Critical Care have launched a pilot study to see if patients with idiopathic pulmonary fibrosis (IPF) can tolerate the addition of a commonly used antiviral drug to standard IPF treatments. The research team believes the drug may ultimately help slow progression of the chronic and progressive disease or reverse its course.